Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension Study

10.1055/s-0041-1728092 ◽

2021 ◽

Author(s):

C Négrier ◽

MV Ragni ◽

KJ Pasi ◽

SW Pipe ◽

I Hegemann ◽

...

Keyword(s):

Interim Analysis ◽

Hemophilia A ◽

Phase 1 ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(16)30430-1 ◽

2017 ◽

Vol 5 (1) ◽

pp. 51-60 ◽

Cited By ~ 66

Author(s):

Noel G McElvaney ◽

Jonathan Burdon ◽

Mark Holmes ◽

Allan Glanville ◽

Peter A B Wark ◽

...

Keyword(s):

Proteinase Inhibitor ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Antitrypsin Deficiency ◽

Open Label Extension ◽

Extension Trial ◽

Inhibitor Treatment

Download Full-text

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.653 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB141

Author(s):

Andrew Blauvelt ◽

Emma Guttman ◽

Iftikhar Hussain ◽

Zhen Chen ◽

Paola Mina-Osorio ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(97)00079-5 ◽

1998 ◽

Vol 8 (1) ◽

pp. 67-75 ◽

Cited By ~ 180

Author(s):

S.L Rogers ◽

L.T Friedhoff

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Interim Analysis ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Open Label Extension

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727072747.793539408 ◽

2017 ◽

Author(s):

Craig Hersh

Keyword(s):

Proteinase Inhibitor ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Antitrypsin Deficiency ◽

Open Label Extension ◽

Extension Trial ◽

Inhibitor Treatment

Download Full-text

26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.370 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB86

Author(s):

Kim A. Papp ◽

Mark G. Lebwohl ◽

Lluís Puig ◽

Jiewei Zeng ◽

Simone Rubant ◽

...

Keyword(s):

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Extension ◽

Extension Trial

Download Full-text

26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.499 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB120

Author(s):

Michael J. Cork ◽

Diamant Thaçi ◽

Lawrence Eichenfield ◽

Peter D. Arkwright ◽

Zhen Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Safety Data ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

Dermatology and Therapy ◽

10.1007/s13555-021-00490-3 ◽

2021 ◽

Author(s):

Kim A. Papp ◽

Saskia de Vente ◽

Jiewei Zeng ◽

Mary Flack ◽

Byron Padilla ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Faculty Opinions recommendation of Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727479881.793555215 ◽

2019 ◽

Author(s):

Roser Torra

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Efficacy And Safety ◽

Polycystic Kidney ◽

Open Label ◽

Delayed Treatment ◽

Open Label Extension ◽

Autosomal Dominant Polycystic Kidney ◽

Extension Trial

Download Full-text

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Schizophrenia Research ◽

10.1016/j.schres.2021.11.030 ◽

2022 ◽

Vol 239 ◽

pp. 83-91

Author(s):

Yuriy Filts ◽

Robert E. Litman ◽

Javier Martínez ◽

Lourdes Anta ◽

Dieter Naber ◽

...

Keyword(s):

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Open Label Extension

Download Full-text